CN106511341B - A kind of medicine for treating chronic bronchitis - Google Patents
A kind of medicine for treating chronic bronchitis Download PDFInfo
- Publication number
- CN106511341B CN106511341B CN201610973466.9A CN201610973466A CN106511341B CN 106511341 B CN106511341 B CN 106511341B CN 201610973466 A CN201610973466 A CN 201610973466A CN 106511341 B CN106511341 B CN 106511341B
- Authority
- CN
- China
- Prior art keywords
- medicine
- chronic bronchitis
- present
- treating chronic
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of medicine for treating chronic bronchitis, described pharmaceutical composition includes the following compounds and pharmaceutically acceptable carrier of effective dose, and the compound has having structure：Wherein R1 is H, CH3Or C2H5.The medicine relieving cough and reducing sputum effect of the present invention is obvious, can significantly improve chronic bronchitis.
Description
Technical field
The present invention relates to field of medicaments, and specifically, the present invention relates to a kind of medicine for treating chronic bronchitis.
Background technology
The main pathophysiological features of chronic bronchitis respiratory disease are the high secreting states of airway mucus, clinical
Being presented with abundant expectoration, to be difficult to expectoration and sputum yellow thick etc., is clinical common common breathing problem.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating chronic bronchitis.
In order to realize the purpose of the present invention, the present invention provides a kind of medicine for treating chronic bronchitis, the medicine group
Compound includes the following compounds and pharmaceutically acceptable carrier of effective dose, and the compound has having structure：
Wherein R1 is H, CH3Or C2H5。
Preferably, R1 H.
Preferably, R1 CH3。
Preferably, R1 C2H5。
It is highly preferred that tablet, capsule, spray, powder spray, nasal drop or injection can be made in the medicine.
The present invention also provides purposes of the compound in the medicine for preparing treatment chronic bronchitis, under the compound has
Array structure：
Wherein R1 is H, CH3Or C2H5。
Preferably, R1 H.
Preferably, R1 CH3。
Preferably, R1 C2H5。
Term " pharmaceutically acceptable " used herein refer to the biological activity that does not eliminate compound as described herein or
The material of property, such as carrier or diluent.This kind of material, which is applied to individual, does not cause undesirable biological action or not
With harmful way with being interacted comprising any component in its composition.
Term " pharmaceutically acceptable carrier " as used herein includes any and all solvent, decentralized medium, bag
Clothing material, surfactant, antioxidant, preservative (such as antiseptic, antifungal agent), isotonic agent, absorption delaying agent, salt,
Preservative, drug stabilizing agent, adhesive, excipient, disintegrant, lubricant, sweetener, flavouring, dyestuff etc. and its combination, this
It is well-known to those skilled in the art (for example, see Remington's Pharmaceutical Sciences, 18th
Ed.Mack Printing Company,1990,pp.1289-1329).In addition to the carrier incompatible with active component, controlling
Consider to use any conventional carrier in treatment or pharmaceutical composition.
The medicine relieving cough and reducing sputum effect of the present invention is obvious, can significantly improve chronic bronchitis.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not the limit to the present invention
System, those skilled in the art according to the present invention basic thought, various modifications may be made or improve, but without departing from this
The basic thought of invention, within the scope of the present invention.
Therapeutic effect of the experimental example medicine of the present invention for chronic bronchitis
Medicine of the present invention：
Cleaning grade kunming mice 100, male and female half and half, 18~22g of body weight.Mouse is divided into treatment group and control group, often
Group 50.Injected in the d1 of experiment with lipopolysaccharides through Respiratory Tract of Mice, since d2 to mouse carry out sootiness, smoke fumigating time 25d,
Sootiness 30min/d, the air flue for carrying out lipopolysaccharides to mouse in sootiness d15 or so inject, and sootiness terminates rear chronic bronchitis
Model establish finish.
Model is successfully established mouse gavaging GUILONG KECHUANNING JIAONANG (every milliliter of drug containing 0.0375g) gavage of rear control group
Dosage 20m1kg-1·d-1, continuous gavage 12d.Gavage (every milliliter of drug containing 0.0375g) is carried out to treatment group mouse
20m1·kg-1·d-1, continuous gavage 12d.
As a result
Muc5ac protein expressions in two groups of airway of mice, TNF-α and IL-8 concentration in bronchoalveolar lavage fluid are determined respectively
Analyzed using the statistics softwares of SPSS 17.0.Analysis result is carried out to inquire into the effect of evaluating medicine of the present invention result, seen
Tables 1 and 2.
Muc5ac determining the protein quantity in 1 pretherapy and post-treatment airway of mice of table
The result of table 1 shows that the air flue Muc5ac protein contents of the slow branch model for the treatment of group mouse are significantly lower than control group, difference
Significantly (P<0.05).
The concentration mensuration of the TNF-α of table 2 and IL-8
By treatment, TNF-α and IL-8 concentration are significantly lower than control group, significant difference (P in treatment group's mouse lung tissue
<0.05)。
Claims (4)
1. compound is in the treatment wherein medicine for the chronic bronchitis patient that airway mucus is in high secreting state is prepared
Purposes, it is characterised in that the compound has having structure：
Wherein R1 is H, CH3Or C2H5。
2. purposes according to claim 1, it is characterised in that R1 H.
3. purposes according to claim 1, it is characterised in that R1 CH3。
4. purposes according to claim 1, it is characterised in that R1 C2H5。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610973466.9A CN106511341B (en) | 2016-11-04 | 2016-11-04 | A kind of medicine for treating chronic bronchitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610973466.9A CN106511341B (en) | 2016-11-04 | 2016-11-04 | A kind of medicine for treating chronic bronchitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106511341A CN106511341A (en) | 2017-03-22 |
| CN106511341B true CN106511341B (en) | 2018-03-16 |
Family
ID=58349797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610973466.9A Expired - Fee Related CN106511341B (en) | 2016-11-04 | 2016-11-04 | A kind of medicine for treating chronic bronchitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511341B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250082A (en) * | 2011-05-05 | 2011-11-23 | 中国人民解放军第四军医大学 | Benzimidazolyl thiazolidinone compounds and synthesis method thereof |
| CN104472562A (en) * | 2014-12-30 | 2015-04-01 | 晁利晓 | Emulsifiable vegetable oil preparation for controlling lepidoptera pests and homopteran pests of crops and preparation method and application of emulsifiable vegetable oil preparation |
-
2016
- 2016-11-04 CN CN201610973466.9A patent/CN106511341B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN106511341A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lehrer | Inhaled biguanides and mTOR inhibition for influenza and coronavirus | |
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| CN111773282A (en) | Medicine and food dual purpose Chinese medicinal preparation and its application | |
| JP6837700B2 (en) | How to use dipivefrine | |
| US11554109B2 (en) | Pemafibrate dosing regimens | |
| CN103446051A (en) | Method for administrating preparations containing peramivir and/or derivatives thereof | |
| CN105078909A (en) | Cisatracurium besilate freeze dried composition for injection and preparation method thereof | |
| CN106511341B (en) | A kind of medicine for treating chronic bronchitis | |
| Aoki | Antiviral drugs for influenza and other respiratory virus infections | |
| CN111759880A (en) | Epimedium herb extract and application thereof in preventing or treating coronavirus | |
| CN102716105A (en) | Dry powder inhalant of interferon Alpha | |
| MX2020010977A (en) | Methods of treating fungal infections. | |
| CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
| CN102641240A (en) | Kukoamine B salt injection and preparation method thereof | |
| CN105541838B (en) | A kind of pharmaceutical composition for treating kidney stone | |
| CN105348171B (en) | A kind of pharmaceutical composition treating knee osteoarthritis | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection | |
| CN107875154A (en) | Composition containing Piperacillin, its pharmaceutical preparation and its application | |
| CN104490893B (en) | A kind of pharmaceutical composition of Cure for insomnia | |
| CN104922103B (en) | Shepherd's purse ramie flavones is preparing the application in anti-anoxic medicine | |
| US20240091167A1 (en) | Use of two-dimensional nanomaterial in inhibition of coronavirus | |
| CN103169970A (en) | Pharmaceutical composition for treating viral pneumonia | |
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| CN105982888A (en) | Combined medicine containing artemisinin and paclitaxel and application of combined medicine | |
| CN103446078A (en) | Method for administrating preparations containing oseltamivir guanidyl carboxylate analogues and/or ethyl esters thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Shi Guangcan Inventor after: Zhang Dongjie Inventor after: Li Mingying Inventor after: Niu Wenyi Inventor before: Gao Yanyun |
|
| CB03 | Change of inventor or designer information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180201 Address after: 453100 No. 88 health Road, Henan, Weihui Applicant after: The First Affiliated Hospital of Xinxiang Medical University Address before: 050000 Hebei province Shijiazhuang City Qiaodong District Huai Road No. 10 Shijiazhuang Boda Biological Technology Co. Ltd. Applicant before: Gao Yanyun |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180316 Termination date: 20181104 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |